Conference News

Read our exclusive conference summaries on aidsmap.com
From 5th - 12th February 2008, aidsmap will be producing a daily email with the latest updates from the 18th Conference on Retroviruses and Opportunistic Infections, Boston, USA.
This email will be translated in French, Spanish, Portuguese, and Russian. Sign up now.
News from the 15th CROI Conference, Boston
- CROI: <i>Kivexa</i> and <i>Truvada</i> have similar efficacy and safety
- CROI: Symptom checklist may help rule out advanced HIV in infants
- CROI: Region of origin and gender significant in long-term changes in CD4 cell count during effective HIV therapy
- CROI: Tetherin: a newly discovered host cell protein that inhibits HIV replication
- CROI: Recreational drug use a risk for asymptomatic heart disorders in HIV-positive patients
- CROI: Risk of lymphomas depends on cumulative viral load and latest CD4 counts
- CROI: Tenofovir plus emtricitabine safe and effective when added to nevirapine for PMTCT
- CROI: Once daily <i>Kaletra</i> tablets non-inferior to twice daily dose
- CROI: Door-to-door Ugandan VCT programme finds more HIV-positive males than females among serodiscordant couples
- CROI: HAART Breastfeeding study detects drug resistance in HIV-infected infants
- CROI: MDR TB cases in South Africa - person-to-person spread likely to be chief cause
- CROI: Large cohorts show excellent responses to ART in developing countries
- CROI: Untreated HIV-positive individuals have a higher risk of death even at CD4 counts over 350
- CROI: Delaying HAART while treating opportunistic infections increases the risk of disease progression and death
- CROI: Herpes virus suppression with valaciclovir lowers viral load in HIV positive women: could work for gay men too
- CROI: Risk of second virological failure has declined since 1996, but risk of death remains stable
- CROI: Biomarker changes may help explain detrimental effects of treatment interruption
- CROI: Nanoparticle technology creates a once-a-month HIV drug
- CROI: Three children in US infected with HIV from pre-chewed food
- CROI: TDM-based PI dose escalation shows modest benefit in black and Hispanic, but not Caucasian, treatment-experienced patients
- CROI: People receiving TB treatment no more likely to die than others who start ARVs
- CROI: AIDS vaccine: additional infection risk restricted to uncircumcised men
- CROI: Darunavir found effective and tolerable in treatment-experienced children and adolescents at 24 weeks
- CROI: Could earlier ART reduce risk of death from non-AIDS related illnesses in people with HIV?
- CROI: Sustained response to hepatitis C treatment lowers liver complications and death in HIV/HCV coinfected people
- CROI: Unplanned pregnancy frequent among women after starting ARVs, need for family planning
- CROI: HAART use in mothers substantially reduces HIV infections in breastfeeding infants in Kisumu, Kenya
- CROI: Extended infant nevirapine prophylaxis reduces HIV transmission through breastfeeding
- CROI: Risk of treatment interruption persists after restarting HAART
- CROI: CCR5 antagonist SCH532706 shows potent activity and good tolerability in small trial
- CROI: Pegylated interferon maintenance therapy demonstrates no benefit in HIV/hepatitis C coinfected individuals
- CROI: DAD cohort finds increased risk of heart attack in people taking abacavir or ddI
- CROI: Lactobacillus supplementation could help reduce vaginal HIV
- CROI: Recurrent hepatitis C in HIV-positive gay men: relapse or reinfection?
- CROI: Vicriviroc appears safe and effective at higher doses in treatment-experienced patients after 48 weeks
- CROI: Once-daily boosted atazanavir comparable to twice-daily Kaletra in treatment-naive patients, with better lipid profile
- CROI: Aciclovir treatment for genital herpes does not reduce HIV acquisition in men or women, major trial shows
- CROI: ARV provision in Africa could cut HIV transmission by 90 per cent
- CROI: Circumcising HIV positive men may increase HIV infections in female partners, but fewer STIs seen
